Optomed: Softening growth prospects

Research Note

2020-10-06

12:01

Redeye sees slower revenue growth ahead and lowers fair value to EUR 7.7 per share. While the company remains fundamentally unchanged, the new reality of digitalisation and social distancing will slow down brand-building and soften camera sales in the months ahead.

GA

Gergana Almquist

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.